Refractory Renal Cell Carcinoma

Drug	Drug Name	Drug Description
DB11800	Tivozanib	A kinase inhibitor to treat adult patients with renal cell carcinoma (RCC) who have failed prior systemic therapies or experienced relapsed disease.

Drug	Drug Name	Target	Type
DB11800	Tivozanib	Cytochrome P450 3A4	enzyme
DB11800	Tivozanib	Serum albumin	carrier
DB11800	Tivozanib	Vascular endothelial growth factor receptor 1	target
DB11800	Tivozanib	Vascular endothelial growth factor receptor 2	target
DB11800	Tivozanib	Vascular endothelial growth factor receptor 3	target
DB11800	Tivozanib	Mast/stem cell growth factor receptor Kit	target
DB11800	Tivozanib	Platelet-derived growth factor receptor beta	target
DB11800	Tivozanib	P-glycoprotein 1	transporter
DB11800	Tivozanib	ATP-binding cassette sub-family G member 2	transporter
DB11800	Tivozanib	Receptor-type tyrosine-protein kinase FLT3	target
DB11800	Tivozanib	Platelet-derived growth factor receptor alpha	target
DB11800	Tivozanib	Protein-tyrosine kinase 6	target
DB11800	Tivozanib	Angiopoietin-1 receptor	target
DB11800	Tivozanib	Fibroblast growth factor receptor 1	target
DB11800	Tivozanib	Hepatocyte growth factor receptor	target

Drug	Drug Name	Phase	Status	Count
DB08885	Aflibercept	1	Active Not Recruiting	1
DB09037	Pembrolizumab	1	Active Not Recruiting	1
DB08875	Cabozantinib	2	Active Not Recruiting	1
DB09073	Palbociclib	2	Recruiting	1